Due to a rate of HER2 amplification or HER2 overexpression of 6–30% in gastric cancer patients [29], the recruitment of large patient cohorts with indication for trastuzumab is difficult and long-lasting. This evidence concerns the gene ERBB2 and gastric cancer.